Sinemet Cr
designed to alleviate motor dysfunction in Parkinson's disease through dopamine replenishment.
Strengths: 25/100mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Sinemet; Caramet; Duodopa; Carbidopa + Levodopa Tablets
- Therapeutic class
Dopamine Precursor / Dopa Decarboxylase Inhibitor
- Pharmacological class
Dopaminergic Agent
- Minor side effects
nausea; dizziness; dry mouth
- Moderate side effects
involuntary movements; confusion; orthostatic hypotension
- Dosage forms
Modified-release tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
MSD
- Onset Time
30–90 minutes
- Duration
4–6 hours
- Storage instructions
Store below 25°C, keep container closed.
- Drug interactions
iron supplements; antipsychotics
- Age restrictions
Not recommended for children.
- Pregnancy and breastfeeding
Pregnancy: Consult healthcare professional. Breastfeeding: Avoid administration.
Contraindications
hypersensitivity to components; narrow-angle glaucoma; concurrent use of non-selective maois
Precautions and warnings
may cause sudden sleep onset; monitor for impulse control disorders; avoid rapid discontinuation
Serious side effects
hallucinations — requires immediate medical attention; malignant syndrome — requires immediate medical attention
Patient summary
designed to alleviate motor dysfunction in Parkinson's disease through dopamine replenishment.
Mechanism of action
Sinemet Cr combines levodopa, which crosses the blood-brain barrier to be converted into dopamine, and carbidopa, which prevents periphery metabolism of levodopa. This allows more active substance to reach the brain to improve movement control.
Sinemet Cr
designed to alleviate motor dysfunction in Parkinson’s disease through dopamine replenishment.
Editorial Notes
- Active ingredient(s): Carbidopa, Levodopa
- Listed indication(s): Parkinson’s Disease
Available option
- 120 tablets - 25/100 mg668-25-100-mg-4185